Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy

Liang Ge; Liang Ge; Xinru You; Jun Huang; Yuejian Chen; Li Chen; Ying Zhu; Yuan Zhang; Xiqiang Liu; Jun Wu; Qian Hai

doi:10.3389/fphar.2018.00582

Frontiers in Pharmacology (Jun 2018)

Human Albumin Fragments Nanoparticles as PTX Carrier for Improved Anti-cancer Efficacy

Liang Ge,
Liang Ge,
Xinru You,
Jun Huang,
Yuejian Chen,
Li Chen,
Ying Zhu,
Yuan Zhang,
Xiqiang Liu,
Jun Wu,
Qian Hai

Affiliations

Liang Ge: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
Liang Ge: School of Pharmacy, Xinjiang Medical University, Ürümqi, China
Xinru You: Key Laboratory of Sensing Technology and Biomedical Instruments of Guangdong Province, School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
Jun Huang: Key Laboratory of Sensing Technology and Biomedical Instruments of Guangdong Province, School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
Yuejian Chen: Nanjing iPharma Technology, Co., Ltd., Nanjing, China
Li Chen: School of Pharmacy, Xinjiang Medical University, Ürümqi, China
Ying Zhu: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
Yuan Zhang: Department of Orthopedics, Xinqiao Hospital, Third Military Medical University, Chongqing, China
Xiqiang Liu: Guangdong Provincial Key Laboratory of Stomatology, Guanghua School of Stomatology, Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China
Jun Wu: Key Laboratory of Sensing Technology and Biomedical Instruments of Guangdong Province, School of Biomedical Engineering, Sun Yat-sen University, Guangzhou, China
Qian Hai: State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China

DOI: https://doi.org/10.3389/fphar.2018.00582
Journal volume & issue: Vol. 9

Abstract

Read online

For enhanced anti-cancer performance, human serum albumin fragments (HSAFs) nanoparticles (NPs) were developed as paclitaxel (PTX) carrier in this paper. Human albumins were broken into fragments via degradation and crosslinked by genipin to form HSAF NPs for better biocompatibility, improved PTX drug loading and sustained drug release. Compared with crosslinked human serum albumin NPs, the HSAF-NPs showed relative smaller particle size, higher drug loading, and improved sustained release. Cellular and animal results both indicated that the PTX encapsulated HSAF-NPs have shown good anti-cancer performance. And the anticancer results confirmed that NPs with fast cellular internalization showed better tumor inhibition. These findings will not only provide a safe and robust drug delivery NP platform for cancer therapy, but also offer fundamental information for the optimal design of albumin based NPs.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords